Kewaunee Scientific (NASDAQ:KEQU) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Kewaunee Scientific (NASDAQ:KEQU - Free Report) from a buy rating to a hold rating in a research report released on Friday morning.

Kewaunee Scientific Stock Performance

Shares of KEQU traded up $3.47 during trading hours on Friday, hitting $51.05. The company had a trading volume of 19,012 shares, compared to its average volume of 22,213. The business has a fifty day moving average of $58.39 and a 200-day moving average of $47.80. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The firm has a market cap of $146.62 million, a price-to-earnings ratio of 8.09 and a beta of 0.71. Kewaunee Scientific has a 12 month low of $30.82 and a 12 month high of $71.33.

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last posted its earnings results on Wednesday, March 12th. The technology company reported $1.09 EPS for the quarter. The company had revenue of $67.17 million for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%.

Remove Ads

Insider Transactions at Kewaunee Scientific

In other news, CFO Donald T. Gardner III sold 1,257 shares of Kewaunee Scientific stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $59.26, for a total value of $74,489.82. Following the completion of the sale, the chief financial officer now directly owns 21,358 shares in the company, valued at approximately $1,265,675.08. The trade was a 5.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Douglas J. Batdorff sold 3,470 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $65.50, for a total value of $227,285.00. Following the completion of the sale, the vice president now owns 5,000 shares of the company's stock, valued at approximately $327,500. This trade represents a 40.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,994 shares of company stock valued at $729,430. 14.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KEQU. Bank of America Corp DE grew its stake in Kewaunee Scientific by 2,605.9% during the fourth quarter. Bank of America Corp DE now owns 460 shares of the technology company's stock worth $28,000 after buying an additional 443 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Kewaunee Scientific during the 4th quarter worth approximately $36,000. JPMorgan Chase & Co. boosted its position in shares of Kewaunee Scientific by 18,000.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock worth $30,000 after acquiring an additional 900 shares in the last quarter. Morgan Dempsey Capital Management LLC bought a new position in Kewaunee Scientific in the fourth quarter valued at approximately $106,000. Finally, Barclays PLC acquired a new position in Kewaunee Scientific during the third quarter valued at approximately $121,000. Institutional investors own 32.69% of the company's stock.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.